New Program to Educate Late-Stage Patients About Pain Management

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

NEW YORK--Medical leaders and prostate cancer patient advocacy groups have joined with Immunex Corporation to launch Empowered Patients in Control (EPIC), an education program designed to help men with late-stage prostate cancer confront the physical and emotional issues related to their disease.

NEW YORK--Medical leaders and prostate cancer patient advocacy groupshave joined with Immunex Corporation to launch Empowered Patients in Control(EPIC), an education program designed to help men with late-stage prostatecancer confront the physical and emotional issues related to their disease.

Said spokesman Harry Belafonte, the noted singer/actor, "it isonly when we stare these problems in the face that we can truly seek tosolve them." Mr. Belafonte was diagnosed with prostate cancer aftera routine checkup and underwent prostatectomy last year.

The goal of the new program is to provide patients, their families,and their physicians with access to the latest information and tools necessaryto improve the management of pain commonly associated with advanced prostatecancer.

The components of EPIC are:

  • The Epic panel comprised of distinguished medical experts, prostatecancer patients, and representatives from leading third-party organizationsadvocating improved treatment of prostate cancer.
  • The EPIC Manual for Patients and Physicians, developed by theEPIC professional panelists, which will include treatment guidelines, therapygoals, patient support materials, and other information. A video for patientsand their families is also being developed.
Related Videos
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content